#phase 2 trial

2 stories

#colorectal cancer #drug valuation #eddingpharm #eli lilly #eloralintide #eloratzp #finance #gb268 #immunotherapy #markets #mounjaro #nmpa

Eddingpharm's GB268 Trial Approved in China
China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial.
BigGo Finance · 1m
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
24/7 Wall St. · 1m